CytoMed Therapeutics develops allogeneic cellular immunotherapies utilizing gamma delta (γδ) T cells and natural killer (NK) cells to target a wide spectrum of solid and hematological cancers. Their proprietary technologies, including induced pluripotent stem cells (iPSCs), enable the creation of cost-effective, off-the-shelf treatments that enhance cancer cell elimination.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments like chemotherapy and radiation can be highly toxic and may not be effective for all patients, especially those with advanced or drug-resistant cancers. Personalized cell therapies offer promise but are often expensive, time-consuming, and limited by the availability of suitable donor cells. This creates a need for readily accessible, cost-effective, and broadly applicable immunotherapies.
Solution
CytoMed Therapeutics develops "off-the-shelf" allogeneic cell therapies using gamma delta (γδ) T cells and natural killer (NK) cells to target a wide range of solid and hematological cancers. By leveraging induced pluripotent stem cell (iPSC) technology, CytoMed creates a scalable and cost-effective platform for generating immune cells with enhanced cancer-killing capabilities. These therapies are designed to recognize and eliminate cancer cells while minimizing harm to healthy tissues, offering a potential alternative or complement to traditional cancer treatments. CytoMed's approach aims to provide readily available and affordable cell-based immunotherapies for a broad spectrum of cancer patients.
Target Audience
The primary target audience includes patients with solid and hematological cancers who are seeking alternative or complementary treatments, as well as oncologists and hematologists looking for more effective and accessible immunotherapeutic options.
Features
- Allogeneic cell therapies based on gamma delta (γδ) T cells and natural killer (NK) cells
- iPSC-derived immune cells for scalable and cost-effective production
- Targeting of a broad spectrum of solid and hematological cancers
- "Off-the-shelf" availability for rapid treatment initiation
- Proprietary technologies to enhance cancer cell elimination
- CAR-γδ T cell technology (CTM-N2D Therapy)
- iPSC-γδ NKT Cell Technology (gdNKT Therapy)